Gilgamesh Pharmaceuticals

About

Gilgamesh Pharmaceuticals provides medicines for psychedelic, novel psychotropic drugs, depression, anxiety, and stress-related disorders.

New York,New York,United States
11 - 50
https://www.gilgameshpharmaceutical.com

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $39M
Industries: Biotechnology,Health Care,Medical,Pharmaceutical
Founded date: Jan 1, 2019
Number Of Employee: 11 - 50
Operating Status: Active
Legal Name: Gilgamesh Pharmaceuticals, Inc.

Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases. Our purpose is to accelerate treatments and fundamentally improve mental health.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

7

$68.55M

Gilgamesh Pharmaceuticals has raised a total of $68.55M in funding over 2 rounds. Their latest funding was raised on Dec 15, 2022 from a Series B round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 15, 2022	Series B	$39M	8	Prime Movers Lab	—	Detail
Apr 14, 2022	Series B	—	1	—	—	Detail
May 6, 2021	Series A	$27M	9	Prime Movers Lab	—	Detail
Nov 25, 2020	Seed	—	1	—	—	Detail
Oct 14, 2020	Seed	—	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

3

18

Gilgamesh Pharmaceuticals is funded by 18 investors. Prime Movers Lab and Y Combinator are the most recent investors.

Investor Name	Lead Investor	Funding Round
Prime Movers Lab	Yes	Series B
Y Combinator	Yes	Seed
Alumni Ventures	—	Series B
Gron Ventures	—	Series B
JLS Fund	—	Series B
Negev Capital	—	Series B
Palo Santo Fund	—	Series B
Route 66 Ventures	—	Series B
Satori Capital	—	Series B
Ayuh Ventures	—	Series B